Welcome to our dedicated page for PLUS THERAPEUTICS news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on PLUS THERAPEUTICS stock.
Plus Therapeutics, Inc. (symbol: PSTV) is a cutting-edge clinical-stage pharmaceutical company based in Austin, Texas. Founded in 1996 and initially known as Cytori Therapeutics, Inc., the company rebranded to Plus Therapeutics in July 2019 to better reflect its mission and evolving focus. Specializing in the discovery, development, and manufacture of innovative treatments for cancer and other debilitating diseases, Plus Therapeutics aims to bring new hope to patients through cutting-edge medical solutions.
The company's lead product candidate is DocePLUS, a protein-stabilized, pegylated liposomal formulation of docetaxel specifically designed for the treatment of small cell lung cancer. Additionally, Plus Therapeutics is developing DoxoPLUS, a generic pegylated liposomal encapsulated doxorubicin aimed at treating breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
In a significant partnership, Plus Therapeutics has entered into a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. This collaboration aims to propel the company further into the forefront of cancer treatment research.
One of the company's groundbreaking developments is the novel injectable radiotherapy called Rhenium (186Re) obisbemeda. This treatment is specifically formulated to deliver targeted high-dose radiation in Central Nervous System (CNS) tumors, optimizing patient outcomes while minimizing off-target risks. The product's efficacy and safety are being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are supported by grants from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas (CPRIT), totaling millions in funding.
Financially, Plus Therapeutics recently secured $6.5 million in upfront gross proceeds, with the potential to receive up to an additional $11.5 million through potential warrant exercise, amounting to approximately $18 million in total gross proceeds. These funds will be essential in advancing the company’s robust pipeline and bringing innovative treatments to market.
Investors and stakeholders can stay informed of the latest developments and financial updates by reaching out to key contacts such as Corey Davis, Ph.D. of LifeSci Advisors, and Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations.
Plus Therapeutics (Nasdaq: PSTV) announced positive interim results from its ReSPECT™ Phase 1 trial of Rhenium NanoLiposome (RNL™) for treating recurrent glioblastoma (GBM). The trial demonstrated RNL's ability to deliver up to 15 times the radiation dose compared to standard external beam therapy, with no significant toxicity observed. All 15 patients in initial cohorts completed treatment, showing promising survival rates, particularly among those not previously treated with bevacizumab. The trial is advancing to its sixth dose escalation cohort, supported by FDA's Orphan Drug and Fast Track designations.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced participation in two virtual investor conferences. The first is the Virtual Fall Investor Summit on November 17, 2020, at 3:00 p.m. ET, followed by the A.G.P. Virtual Healthcare Symposium on November 19, 2020. Investors can arrange virtual 1x1 meetings with management. A live webcast of the first summit will be available on the company’s website. Plus Therapeutics focuses on innovative radiotherapeutic solutions for cancer treatment using a unique nanotechnology platform.
Plus Therapeutics (PSTV) will host a webinar on November 19, 2020, discussing interim data from the ReSPECT Phase 1 clinical trial for Rhenium NanoLiposome (RNL) in treating recurrent glioblastoma (GBM). The company recently received Orphan Drug and Fast Track designations from the FDA for RNL. The webinar will detail interim findings regarding safety, tolerability, and efficacy, presented by Dr. Andrew Brenner, a key figure in the trial. The ReSPECT trial aims to fully enroll by the end of 2020, highlighting a significant step in addressing the unmet medical needs in GBM treatment.
Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company focused on nanoliposome-encapsulated radionuclides targeting various cancer types, including recurrent glioblastoma. The company is set to present at the virtual Fall Investor Summit scheduled for November 16-18, 2020. This summit will feature 75 companies and engage over 300 institutional and retail investors, providing a platform for fostering connections between smallcap and microcap firms and potential investors.
Plus Therapeutics (Nasdaq: PSTV) has announced the formation of a Scientific Advisory Board (SAB) to enhance its research and development efforts in the fields of neuro-oncology, preclinical drug development, and nanotechnology. The SAB will offer guidance for the advancement of the company’s innovative treatments, including its lead investigational drug, Rhenium NanoLiposomes (RNL™), aimed at treating recurrent glioblastoma. The board comprises notable experts, including Andrew Brenner, John McKew, and Vladimir P. Torchilin, whose collective experience is expected to strengthen Plus Therapeutics' drug development initiatives.
Plus Therapeutics announces the initiation of the sixth cohort in its NCI-supported ReSPECT™ Phase 1 clinical trial, targeting recurrent glioblastoma with Rhenium NanoLiposomes (RNL™). This progression follows a successful fifth cohort, backed by the Data and Safety Monitoring Board’s clearance. Cohort six will increase both the drug volume to 8.8 mL and radiation dose to 22.3 millicuries. This trial is part of Plus Therapeutics’ strategy to enhance treatment efficacy for glioblastoma, with interim data presentation scheduled for the 2020 SNO Annual Meeting in November.
Plus Therapeutics (PSTV) received FDA Orphan Drug and Fast Track designations for its glioblastoma treatment Rhenium NanoLiposome (RNL). The company reported a third-quarter net loss of $1.7 million or $(0.39) per share, compared to a net income of $0.5 million or $(0.03) per share in Q3 2019. The cash balance decreased to approximately $7.6 million from $17.6 million at the end of 2019. The ReSPECT Phase 1 trial continues with enrollment in the sixth cohort approved. A conference call is scheduled for October 22, 2020, to discuss these results.
On October 15, 2020, Plus Therapeutics (Nasdaq: PSTV) announced its participation in the upcoming Cancer Innovation Summit hosted by Health Tech Austin, scheduled for October 22 from 12:00 to 3:00 p.m. EDT. Gregory Stein, M.D., Senior Vice President of Clinical Development, will present at the Cancer Drug Showcase, highlighting innovative cancer technologies. This summit aims to unite leaders to share insights on cancer innovation. Plus Therapeutics focuses on developing nanoliposome-encapsulated radionuclides targeting rare cancers, leveraging its unique nanotechnology platform for safer, more effective treatments.
Plus Therapeutics, Inc. (Nasdaq: PSTV) will release its third quarter 2020 financial results on October 22, 2020, after market close. A conference call will follow at 5:00 p.m. ET for management to discuss these results and provide corporate updates. The call will include a live webcast and can be accessed through their official IR page. Plus Therapeutics focuses on developing nanoliposome-encapsulated radionuclides targeted at rare cancers, aiming to enhance patient treatment through innovative drug delivery methods.
Plus Therapeutics, Inc. (Nasdaq: PSTV) has appointed five experts to its Clinical Advisory Board to enhance its efforts in developing nanoscale radiotherapeutics for rare brain cancers. The new members include leaders in neurological surgery and neuro-oncology from prestigious institutions. CEO Marc H. Hedrick emphasized the importance of their expertise in navigating clinical challenges, particularly for glioblastoma patients. Plus Therapeutics focuses on innovative drug delivery mechanisms, aiming to improve treatment efficacy and safety for patients.
FAQ
What is the current stock price of PLUS THERAPEUTICS (PSTV)?
What is the market cap of PLUS THERAPEUTICS (PSTV)?
What is Plus Therapeutics, Inc.?
What are the main products of Plus Therapeutics?
What is Rhenium (186Re) obisbemeda?
What partnerships does Plus Therapeutics have?
What recent financial achievements has Plus Therapeutics made?
Where is Plus Therapeutics headquartered?
What clinical trials is Plus Therapeutics involved in?
Who can investors contact for more information?
What was the former name of Plus Therapeutics?
When was Plus Therapeutics founded?
